CTRI/2019/02/017603尚未招募1/2 期
Evaluation of crestal bone loss and implant stability between two different crest module implants
Sravya Reddy1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2019年12月2日最近更新:
试验速览
- 阶段
- 1/2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Crestal bone level and implant stability will be recorded
研究概览
简要总结
Patients will beselected from outpatient department of Periodontics, Kamineni Institute OfDental Sciences, Narketpally, and Nalgonda. Selected patientsaged between 20-55 years of age and Patientswith single or multiple edentulous areas are selected to evaluate crestal bone loss and implant stability between two different crest module designs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 20.00 Year(s) 至 55.00 Year(s)(—)
- 性别
- All
入选标准
- •Patients with single or multiple edentulous areas with an age range between 20-55 years.
排除标准
- •Pregnant women and lactating mothers, Patients on medication which effects bone metabolism.
结局指标
主要结局
Crestal bone level and implant stability will be recorded
时间窗: Crestal bone level and implant stability will be recorded using peri apical radiographs and device PENGUINRFA at baseline, 4 weeks, and 12 weeks.
次要结局
- Crestal bone level and implant stability is recorded using peri-apical radiographs and device penguin to measure RFA values(baseline, 1month, 3months)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
Implant Placement With Reverse Drilling TechniqueCTRI/2023/08/056711Dr Syed Afzal24
尚未招募
1 期
Estimation of bone loss around two different collar implantsCTRI/2019/02/017603Sravya Reddy
招募中
不适用
Evaluation of Different Attachments on Implant-Retained Mandibular Overdenture.Edentulism in Lower JawEdentulismNCT06721377Al-Azhar University10
已完成
不适用
Radiographic Evaluation of All-on-4 Implant Prosthesis With Different Materials and Bar Construction TechniquesBone LossNCT06071689Mansoura University18
已完成
3 期
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic AcidOsteoporosisNCT00097812Novartis Pharmaceuticals220
